Velano taps $25M in new funding for its needle-free, bedside blood draw system

Red blood cells
Velano's PIVO device allows practitioners to collect as much blood as needed while the patient is in the hospital without additional needle sticks. (Wikimedia Commons)

Velano Vascular, maker of a needle-free blood draw system, has closed a second tranche of new financing with $25 million to put toward its commercialization and launch of additional access products and medical devices for the inpatient setting.

The funding follows up on an initial tranche of $10 million, secured by the company this past May. That included backing from Intermountain Healthcare—which previously rolled out the former Fierce 15 winner’s blood collection technology across all 22 of its Utah-area hospitals—as well as from other investors, entrepreneurs and philanthropists.

“We are thrilled to welcome new and returning investors as we continue to establish a more humane global standard for hospital practice at the intersection of blood collection, vascular access and infection prevention,” Velano CEO Eric Stone said in a statement. A list of investors for the latest raise was not disclosed.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Cleared by the FDA in 2017, Velano’s PIVO device attaches to a patient’s IV and pushes a small flexible catheter through the line and into the vein—past the debris, medication and fluids that may collect at the end of the tube and otherwise taint or block a blood sample.

The device allows practitioners to collect as many tubes or syringes of blood as needed while the patient is in the hospital without additional needle sticks.

RELATED: FierceMedTech’s 2017 Fierce 15 | Velano Vascular

“Commercial demand for PIVO and our family of novel solutions is being driven by a move to One-Stick Hospitalization and a growing realization that removing needles from blood draws improves the patient experience, protects practitioners and boosts the bottom line,” Stone added. This year, the San Francisco-based company marked its one-millionth PIVO procedure.

The funding this year also helped support the construction of a new U.S. manufacturing line, after Velano expanded the use of its blood collection technologies to 10 states and dozens of hospitals in 2018.

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.